- Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flopsCNBC
- Pfizer Stops Developing Weight-Loss PillBloomberg Television
- Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with ObesityYahoo Finance
- Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effectsCNBC